The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
KoenigsmannM., KnaufW., HeroldM.Fludarabine and bendamustine in refractory and relapsed indolent lymphoma—a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma.2004; 45(9): 1821–1827.
2.
KathR., BlumenstengelK., FrickeH.J., HöffkenK.Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol.2001; 127(1): 48–54.
3.
BremerK.High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol.2002; 128(11): 603–609.
4.
HeroldM., SchulzeA., NiederwieserD.Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol.2006; 132(2): 105–112.
5.
EichbaumM.H., SchuetzF., KhbeisT.Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs.2007; 18(8): 963–968.
6.
BottkeD., BatheK., WiegelT., HinkelbeinW.Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol.2007; 183(3): 128–132.
7.
KösterW., HeiderA., NiederleN.Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol.2007; 2(4): 312–316.
8.
WeideR., HeymannsJ., GoresA., KöpplerH.Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma.2002; 43(2): 327–331.
9.
WeideR., PandorfA., HeymannsJ., KöpplerH.Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well-tolerated outpatient chemo-immunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma.2004; 45(12): 2445–2449.
10.
RummelM.J., Al-BatranS.E., KimS.Z.Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol.2005; 23(15): 3383–3389.
11.
WeideR., HessG., KöpplerH.High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma.2007; 48(7): 1299–1306.
12.
BergmannM.A., GoebelerM.E., HeroldM.Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica.2005; 90(10): 1357–1364.
13.
LissitchkovT., ArnaudovG., PeytchevD., MerkleK.H.Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol.2006; 132(2): 99–104.
14.
HartmannJ.T., MayerF., SchleicherJ.Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German Sarcoma Group (AIO-001). Cancer.2007; 110(4): 861–866.
HeiderA., NiederleN.Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs.2001; 12(9): 725–729.
17.
WeidmannE., KimS.Z., RostA.Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol.2002; 13(8): 1285–1289.
18.
FriedbergJ.W., CohenP., ChenL.Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol.2008; 26(2): 204–210.
19.
ReichmannU., BokemeyerC., WallwienerD., BambergM., HuoberJ.Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol.2007; 18(12): 1981–1984.
20.
Schmidt-HieberM., SchmittelA., ThielE., KeilholzU.A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res.2004; 14(6): 439–442.
21.
KollmannsbergerC., GerlA., SchleucherN.Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs.2000; 11(7): 535–539.
22.
SchmittelA., KnödlerM., HortigP., SchulzeK., ThielE., KeilholzU.Phase II trial of second-line bendamustine chemo therapy in relapsed small cell lung cancer patients. Lung Cancer.2007; 55(1): 109–113.
23.
SchoppmeyerK., KrethF., WiedmannM., MössnerJ., PreissR., CacaK.A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs.2007; 18(6): 697–702.
24.
HöffkenK., MerkleK., SchönfelderM.Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol.1998; 124(11): 627–632.
25.
von MinckwitzG., ChernozemskyI., SirakovaL.Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydro chloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs.2005; 16(8): 871–877.
26.
PönischW., MitrouP.S., MerkleK.Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol.2006; 132(4): 205–212.
27.
BajettaE., BiganzoliL., CarnaghiC.Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. Cancer.1998; 83(6): 1136–1141.
28.
LabiancaR., CascinuS., FrontiniL.High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a “GIS-CAD” phase III study. Italian Group for the Study of Digestive Tract Cancer. Ann Oncol.1997; 8(2): 169–174.
29.
ErlichmanC., FineS., KerrI.: Experience with 5FU + L-leucovorin. Adv Exp Med Biol.1993; 339: 77–79.
30.
GebbiaV., TestaA., ValenzaR.: A phase-II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma. Oncology.1993; 50(6): 490–494.
31.
ScheithauerW., KornekG., MarczellA.Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure L-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol.1997; 15(3): 908–914.
32.
GebbiaV., ValenzaR., TestaA.: Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer.1994; 30A(11): 1734–1736.
33.
TournigandC., CervantesA., FigerA.OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GER-COR study. J Clin Oncol.2006; 24(3): 394–400.
34.
ValoneF.H., GandaraD.R., LuceJ.A.: Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol.1993; 32(3): 215–220.
35.
PapadimitrakopoulouV.A., DimeryI.W., LeeJ.J., PerezC., HongW.K., LippmanS.M.Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the MD Anderson Cancer Center Experience. Cancer J Sci Am.1997; 3(2): 92–99.
36.
CaponigroF., ComellaP., DaponteA.: A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck. Oncology Rep.1997; 4: 1207–1211.
37.
ComellaP., De VitaF., MancarellaS.Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol.2000; 11(10): 1323–1333.
